Comprehensive genomic profiling of metastatic tumors in a phase II biomarker study of everolimus in advanced renal cell carcinoma

PURPOSE: Genomic events leading to activation of mechanistic target of rapamycin (mTOR) are common in renal cell carcinoma (RCC). Everolimus is an allosteric mTOR inhibitor with efficacy in metastatic RCC (mRCC). We characterized the genomic profile of RCC tumors from metastatic sites and assessed w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Genitourin Cancer
Main Authors: Gao, Xin, Jegede, Opeyemi, Gray, Connor, Catalano, Paul J., Novak, Jesse, Kwiatkowski, David J., McKay, Rana R., George, Daniel J., Choueiri, Toni K., McDermott, David F., Signoretti, Sabina, Bhatt, Rupal S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6175670/
https://ncbi.nlm.nih.gov/pubmed/29754934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.04.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados